Navigation Links
Hadasit Bio-Holdings Flagship Portfolio Company Enlivex Awarded Orphan Drug Status for ApoCell Treatment by the FDA
Date:4/4/2013

d on normal biological activity and initiates a state of immune tolerance.  This mechanism is naturally called into action by the body when removing cells that are in the process of programmed cell death (apoptosis).  ApoCell launches this mechanism into action during the window of opportunity for treatment, close to the time of the bone marrow transplant.

"Receiving orphan drug status from the FDA is an important regulatory recognition of the drug's necessity," said Ophir Shahaf , CEO Hadasit Bio-Holdings.  "The future development track of the drug is relatively short, and the company expects regulatory relief along with tax breaks as part of the approval of the drug's orphan status.  This approval paves the way for the continued advancement and clinical development of the drug, and towards entering the American market that is estimated to be in the hundreds of millions of dollars annually.  The exclusivity section provides assurance in protecting the product from competition, and the status as a whole instills an advantage in the regulatory process with the authorities, creating a significant competitive edge and building value for our shareholders."

For more information about Enlivex and ApoCell please visit: www.enlivexpharm.com

For more information about Hadasit Bio-Holdings please visit: www.hbl.co.il

Contact:
KCSA Strategic Communications
Phil Carlson / Josh Dver
212-896-1233 / 1239
pcarlson@kcsa.com / jdver@kcsa.com


'/>"/>
SOURCE Hadasit Bio-Holdings Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Hadasit Bio-Holdings Portfolio Companies Receive Funding to Support Clinical Trial Preparations and Obtain Regulatory Approvals in U.S. and Europe
2. Projecis Demonstrates Flagship Project Management Software at Outsourcing Clinical Trials-West in San Francisco
3. TPI Provides Further Updates on its GMOL Flagship Product
4. Alliqua Initiates Life-Cycle Management Plan to Expand Wound Care Portfolio for Use in Broader Wound Indications
5. Emerging Data From Upsher-Smiths CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
6. SAFC Expands PharmaGrade Raw Materials Portfolio to Meet Growing Demand; Expects to Double PharmaGrade Portfolio in 2013
7. Amedica Expands Patent Portfolio with Proprietary Silicon Nitride Total Disc Implant to Treat Neck and Back Pain
8. Mylan Launches Innovative Portfolio of Antiretroviral Products for Treatment of HIV/AIDS in South Africa
9. Unilife to Showcase Broad Portfolio of Innovative, Differentiated Injectable Drug Delivery Systems at Pharmapack Europe
10. Ferring Pharmaceuticals Inc. Recognized for Best-in-Class Work-Life Portfolio
11. Elekta to Showcase Broad Portfolio of Cancer Management Solutions at 2013 Arab Health Congress and Exhibition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... Drug Administration (FDA) has removed the clinical hold ... SWOG,s ongoing Phase 1b/2 clinical trial (S1313). The ... PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with ... pancreatic adenocarcinoma.  The study will resume under a ...
(Date:9/18/2014)... 2014 Australian biomarker discovery company Minomic International ... its MiStat™ prostate cancer screening test, planning to achieve ... completion. Minomic,s proprietary MiStat™ technology is a ... proprietary biomarker known as the MIL-38 antigen. This biomarker ... Researchers at 11 leading urology centres ...
(Date:9/18/2014)... , Sept. 18, 2014 /CNW/ - A new expert ... Canada , released today by the ... safe and effective medicines for children. Each year about ... children use at least one prescription drug. Much of ... from the authorized use), creating potential health risks. ...
Breaking Medicine Technology:SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
... 17, 2011 Pharmatek Laboratories, Inc., a premier ... industry, announced that it has been approved by ... the analysis of Schedules I through V controlled ... manufacture drug products containing Schedules IV and V ...
... 2011 The U.S. Food and Drug Administration today ... with methotrexate, for the treatment of active systemic ... years and older. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... a rare, potentially life-threatening disorder in children that ...
Cached Medicine Technology:Pharmatek Granted Approval by the DEA for Analysis of All Controlled Substances 2FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 2FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 3
(Date:9/18/2014)... Clinical trial report, “Edema Global Clinical Trials ... trial scenario. This report provides elemental information and data ... an overview of the trial numbers and their recruitment ... the globe. The databook offers a preliminary coverage of ... of the sponsors and also provides briefing pertaining to ...
(Date:9/18/2014)... This past August, Narconon Louisiana New Life ... the kissing booth during the West Feliciana Animal Humane Society fundraiser ... have loved animals my whole life and have always had animals ... strays who needed a home. Supporting an animal shelter allows ... all home!” , The CEO of Narconon Louisiana was there not ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Relias Learning, the ... and human services markets, today announced it has been named ... growing private companies in America. , In the three-year period ... moved up almost 2,000 spots on the Inc. 5000 list ... , “The industries we serve continue to grow, ...
(Date:9/18/2014)... The new BuildClean™ Dust Control ... and homeowners alike as it eliminates the top ... causes potential health issues, and makes it “unlivable” ... system allows contractors to virtually eliminate airborne dust ... remodeling tasks. , BuildClean removes up to 90 ...
(Date:9/18/2014)... Salamon HealthDay Reporter ... midlife may be associated with increased odds of developing ... new research suggests. The study, which did not ... also suggested that the migraine-Parkinson,s association was stronger in ... a warning sign of a pending attack that includes ...
Breaking Medicine News(10 mins):Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 4Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 2Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 3
... a newborn baby going under the knife to repair a ... work begins for parents. University of Alberta nursing professor Gwen ... a former pediatric cardiology nurse; she wanted to find out ... per cent convinced that health-care professionals get what these parents ...
... 26 The Providence Service,Corporation (Nasdaq: PRSC ) ... financial advisor. , In ... strategic,options relating to, among other things, delevering its debt, growing ... UBS,Investment Bank has been retained in connection with selling certain,non-strategic ...
... Stylists, beauticians may be affected by phthalates in these ... -- Mothers exposed to a common hairspray chemical while ... born with an abnormally placed urinary opening, a new ... fragrances, and nail and hair products contain chemicals called ...
... are misaligned and point outward are at significantly ... adulthood, according to findings of a Mayo Clinic ... ( http://pediatrics.aappublications.org/cgi/content/full/122/5/1033 ), the official journal of the ... examined the medical records of 407 patients with ...
... it,s cheaper and less time-consuming than in-person visits, study ... counseling may be as effective as face-to-face counseling in ... University of Florida study included 234 obese women, ages ... Florida. , All the women completed a six-month weight-loss ...
... Public engagement practitioners from across the world are to ... be held in South Africa, organised by the Wellcome ... engage to empower" will take place from 2-5 ... Studies, KwaZulu-Natal. It will bring together practitioners working in ...
Cached Medicine News:Health News:Parents are the unsung heroes 2Health News:Providence Service Corporation Retains UBS Investment Bank as its Financial Advisor in Connection With the Sale of Certain Non-Strategic Assets 2Health News:Over-the-Phone Weight Loss Counseling Works 2Health News:International workshop aims to boost public engagement work in developing countries 2Health News:International workshop aims to boost public engagement work in developing countries 3
... two-piece Titanium (Ti-6Al-4V) screw offered in two ... of lengths. The two pieces are loaded ... A single instrument set contains all items ... Standard and Mini Kompressor Compression Screws. , ...
... The cornerstones of the Acutrak family ... Screw Systems. Together they are used primarily ... of the upper extremity, but have been ... The bones stabilized with these two systems ...
... combined with the IRIS Medical OcuLight ... consoles,the EasyView slit lamp adapter (SLA) ... laser photocoagulation,to your existing Haag-Streit slit ... and glaucoma,without compromising the diagnostic functions ...
... revolutionized the wrist arthroplasty market with the ... We're at it again, with the release ... Like the original, the Universal2 System continues ... debilitating arthritis. To date, we now have ...
Medicine Products: